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ABSTRACT
Objectives: To investigate the prospects of newly
available benchtop sequencers to provide rapid
whole-genome data in routine clinical practice.
Next-generation sequencing has the potential to
resolve uncertainties surrounding the route and timing
of person-to-person transmission of healthcare-
associated infection, which has been a major
impediment to optimal management.
Design: The authors used Illumina MiSeq benchtop
sequencing to undertake case studies investigating
potential outbreaks of methicillin-resistant
Staphylococcus aureus (MRSA) and Clostridium difﬁcile.
Setting: Isolates were obtained from potential
outbreaks associated with three UK hospitals.
Participants: Isolates were sequenced from a cluster
of eight MRSA carriers and an associated bacteraemia
case in an intensive care unit, another MRSA cluster of
six cases and two clusters of C difﬁcile. Additionally, all
C difﬁcile isolates from cases over 6 weeks in a single
hospital were rapidly sequenced and compared with
local strain sequences obtained in the preceding
3 years.
Main outcome measure: Whole-genome genetic
relatedness of the isolates within each epidemiological
cluster.
Results: Twenty-six MRSA and 15 C difﬁcile isolates
were successfully sequenced and analysed within
5 days of culture. Both MRSA clusters were identiﬁed
as outbreaks, with most sequences in each cluster
indistinguishable and all within three single nucleotide
variants (SNVs). Epidemiologically unrelated isolates
of the same spa-type were genetically distinct ($21
SNVs). In both C difﬁcile clusters, closely
epidemiologically linked cases (in one case sharing the
same strain type) were shown to be genetically distinct
($144 SNVs). A reconstruction applying rapid
sequencing in C difﬁcile surveillance provided early
outbreak detection and identiﬁed previously
undetected probable community transmission.
Conclusions: This benchtop sequencing technology is
widely generalisable to human bacterial pathogens. The
ﬁndings provide several good examples of how rapid
and precise sequencing could transform identiﬁcation of
transmission of healthcare-associated infection and
therefore improve hospital infection control and patient
outcomes in routine clinical practice.
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ARTICLE SUMMARY
Article focus
- To investigate the prospects of newly available
benchtop sequencers to provide rapid whole-
genome data in routine clinical practice.
- In particular to investigate the potential of such
technology for identiﬁcation of transmission
events of healthcare-associated pathogens.
Key messages
- We demonstrate benchtop sequencing can
enhance hospital infection control through high
precision support and rejection of transmission
using genetic data.
- Whole-genome data provided additional genetic
resolution over existing genetic typing strategies.
- We also show this technology offers turnaround
times of under a week in a format that, in
contrast to molecular typing, is organism
independent.
Strengths and limitations of this study
- The case studies presented provide several good
examples of how rapid and precise sequencing
could transform identiﬁcation of transmission of
healthcare-associated infection.
- Given this is a pilot study, further evaluations of
the impact of this technology on hospital
infection control are required. However, this
study provides a clear rationale for future work
undertaking formal comparisons of benchtop
sequencing with existing local and national
typing schemes.
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Open Access ResearchBACKGROUND
Uncertainty about the exact route and timing of trans-
mission is a major impediment to management of
healthcare-associated infection, particularly for endemic
pathogens that are also carried commensally, such as
Staphylococcus aureus and Clostridium difﬁcile. This
problem impairs the development and implementation
of effective evidence-based measures for infection
control.
1
High-throughput methods using next-generation
sequencing (NGS) are revolutionising bacterial geno-
mics, providing sufﬁcient resolution potentially to
determine which cases within temporo-spatial clusters
are likely to be related.
2e5 With the advent of rapid
sequencers, sources of outbreaks have been identiﬁed in
clinically relevant timescales, demonstrating the poten-
tial of NGS to transform infection control practice.
6e8
The latest benchtop machines offer whole-genome
sequencing in a format and at a cost accessible to routine
hospital laboratories,
9 but the practical prospects for
their use are unclear.
Here, we apply benchtop NGS in near real time to four
case studies and to a surveillance reconstruction,
involving two important healthcare-associated patho-
gens, S aureus and C difﬁcile. We demonstrate how NGS
supports identiﬁcation of outbreaks of closely genetically
related cases, including highlighting potential genetic
links between cases not previously known to be related.
In other examples, we show how NGS can refute trans-
mission between cases that are epidemiologically linked,
including between cases sharing the same strain type,
indicating the additional beneﬁt benchtop sequencing
may provide over existing typing strategies.
METHODS
Setting and patients, Oxford-based case studies
The Oxford University Hospitals NHS Trust (OUH)
comprises 1600 beds across four hospitals, three in
Oxford and one 35 miles north in Banbury. It provides
>90% of hospital care, and all acute services, to
w600000 people in Oxfordshire, UK. The OUH
microbiology laboratory provides all diagnostic testing
for S aureus and C difﬁcile for the region. All cases from
three suspected outbreaks between July and October
2011 underwent NGS in parallel with routine infection
control investigation (ﬁgure 1). A cluster of carriers of
an atypical methicillin-resistant S aureus (MRSA) strain in
an intensive care unit (ICU), with an associated blood-
stream infection (MRSA cluster 1) was investigated. All S
aureus isolates from patients in this ICU in the following
month were sequenced, ﬁrst to establish the level of
diversity among S aureus isolates from the ICU to provide
a comparison with the potential outbreak data and
second to conﬁrm control of the MRSA outbreak.
Isolates were sequenced irrespective of resistance
phenotype. The ICU is a 40 bedded unit offering high
dependency and intensive care. Brieﬂy, baseline infec-
tion control interventions included daily environmental
cleaning, cleaning of equipment between patients and
use of ‘aseptic non-touch technique’ for all line inser-
tion, use and care. However, MRSA carriers were not
routinely isolated. No other MRSA carriers were identi-
ﬁed on the ICU in the month prior to the outbreak and
only one in the 2 months following. Two clusters of C
difﬁcile infection (CDI, C difﬁcile clusters 1 and 2) from
a medical ward and an elective surgical unit were also
investigated. OUH infection control policy targeting C
difﬁcile is described in a previous publication.
10
Setting and patients, Health Protection Agency S aureus
case study
A possible MRSA outbreak reported to the national
Health Protection Agency affecting six patients in
southern England between July and September 2011 was
investigated (ﬁgure 1, MRSA cluster 2). All isolates
possessed the lukS and lukF genes encoding
PantoneValentine leukocidin. Two additional local
isolates that shared the same staphylococcal protein A
(spa)-type, but without an epidemiological connection to
the cluster, were also included as controls.
Setting and patients, Oxford-based surveillance
reconstruction
To investigate the potential of fast turnaround benchtop
sequencing as a surveillance tool, all CDI cases from one
of the OUH hospitals over a 6-week period (July to
August 2010) were sequenced by MiSeq. Although
prepared and sequenced together, samples were
analysed sequentially in the order originally sent to the
routine clinical laboratory to mimic how NGS could
support a real infection control investigation. Sequence
data obtained on the Illumina (San Diego, California,
USA) GAIIx and HiSeq platforms from 1185 of 1460
samples taken between September 2007 and June 2010
from a previously described collection of all Oxfordshire
CDI cases
10 were available for comparison.
Samples and sequencing
S aureus isolates were obtained from clinical samples
inoculated onto MRSASelect agar (Bio-Rad, Hemel
Hempstead, UK). Antimicrobial sensitivities were deter-
mined by disc diffusion and E testing as per European
Committee on Antimicrobial Sensitivity Testing guide-
lines.
11 C difﬁcile isolates were identiﬁed following
selective culture
12 of toxin enzyme immunoassay-positive
diarrhoeal faecal samples.
For both organisms, DNA was extracted using
a commercial kit (QuickGene, Fujiﬁlm, Tokyo, Japan),
from a single colony subcultured onto a Columbia blood
agar plate and incubated for 24e48 h. A combination of
standard Illumina and adapted protocols was used to
produce multiplexed paired-end libraries (DNA frag-
ments with each sample’s DNA tagged with a unique
index). Pools of four samples were sequenced at the
Wellcome Trust Centre for Human Genetics, Oxford,
UK, using sequencing-by-synthesis technology,
13 on the
Illumina MiSeq platform, generating 150 base paired-
end reads.
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Rapid benchtop sequencing of Staphylococcus aureus and Clostridium difﬁcileSequence assembly and analysis
Sequence read data were analysed and assembled using a
pipeline developed speciﬁcally for bacterial sequencing,
as follows: to measure genome-wide sequence similarity,
the full set of properly paired reads from each isolate was
mapped using Stampy
14 V.1.0.11 (without BWA pre-
mapping, using an expected substitution rate of 0.01), to
either S aureus MRSA252 (GenBank: NC_002952)
15 or C
difﬁcile 630 (GenBank: AM180355), CD630.
16 Single
nucleotide variants (SNVs) were identiﬁed across all
mapped non-repetitive sites using SAMtools
17 mpileup,
after parameter tuning based on bacterial sequences.
Known mobile genetic elements in CD630 were
excluded from the analysis, as they account for 11% of
the genome,
16 and exchange of a single element may
result in multiple SNVs in one event. A consensus of at
least 75% was required to support an SNV, and calls were
required to be homozygous under a diploid model. Only
SNVs supported by at least ﬁve reads, including one in
each direction, which did not occur at sites with unusual
depth and were not within 12 bp of other variants, were
accepted. Maximum likelihood trees were estimated
from the mapped whole genomes using PhyML
18 using
a JukeseCantor model. To identify variation in gene
content, sequence reads were assembled de novo using
Velvet V.1.0.18,
19 with parameter values optimised to
maximise n50 (50% of the assembly in contigs equal
to or larger than this value). These assemblies were used
to identify antibiotic resistance genes for S aureus and to
determine in silico multilocus sequence types (MLST)
12
for C difﬁcile.
To assess both MiSeq data quality and its comparability
with existing HiSeq data, the MRSA252 and CD630
references and one other isolate of each organism were
sequenced on both platforms. Duplicates of two of the S
aureus isolates from MRSA cluster 1 and an MRSA252
sample were run on MiSeq as controls.
Ethics statement
Ethical approval for sequencing S aureus and C difﬁcile
isolates from routine clinical samples and linkage to
patient data without individual patient consent was
obtained from Berkshire Ethics Committee (10/H0505/
83) and the UK National Information Governance Board
Figure 1 Clusters and samples. All clusters of cases occurred in the Oxford University Hospitals NHS Trust between July and
October 2011, apart from MRSA cluster 2 where samples were obtained by the Health Protection Agency from an outbreak in
southern England between July and September 2011. CDI, Clostridium difﬁcile infection: $3 unformed stools in 24 h, enzyme
immunoassay positive, culture positive.
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Rapid benchtop sequencing of Staphylococcus aureus and Clostridium difﬁcile(8-05(e)/2010). The Health Protection Agency has
Patient Information Advisory Group approval to hold
and analyse surveillance data for public health purposes
under Section 60 of the Health and Social Care Act 2001.
RESULTS
Twenty-six S aureus isolates (from 24 patients) and 15 C
difﬁcile isolates (from 15 patients) (ﬁgure 1) were
sequenced using the MiSeq benchtop sequencer. Mean
read-depths for S aureus and C difﬁcile were 77.6 and 50.4,
respectively, and reference genome coverages were
82.7% and 79.5%, respectively, after quality ﬁltering (see
supplementary ﬁgures 1e3 for regions called; uncalled
regions include repetitive regions which, in contrast to
Sanger sequencing, 150 bp reads cannot cover, and
mobile elements, as well as other non-core genome).
The entire process from commencing DNA extraction to
measuring genomic relatedness for each set of
sequences was completed within ﬁve working days of
culture. No sequence differences were detected in the
two pairs of replicates: between CD630 and MRSA252
and published reference sequences or between four
samples sequenced both with MiSeq and earlier with
HiSeq.
NGS supports a ward outbreak, despite discordant
antimicrobial and strain-typing data (MRSA cluster 1)
Ten MRSA isolates obtained from eight patients from
the same ICU over 4 months belonged to the same spa-
type (t5973) and were indistinguishable by pulsed-ﬁeld
gel electrophoresis (PFGE) (ﬁgure 2A,B). Ward stays
and the ﬁrst positive isolate per patient are shown in
Figure 2 Staphylococcus aureus cluster genetic and epidemiological relationships. (A and B) MRSA cluster 1 and related MSSA
isolates. (C and D) MRSA cluster 2. Panel A shows all isolates from MRSA cluster 1 (white circles) and all S aureus isolates from
the following month (grey circles, all methicillin sensitive). The left panels show the genetic relationships between cases as
maximum likelihood trees, labelled with the number of single nucleotide variants at which samples differ. Genetically
indistinguishable samples are shown in the same circle. The right panels show time spent on the same ward as a horizontal line for
each case in both clusters. In panel B, the dashed line indicates time on the same ward and the solid line time in the same bay. In
panel D, the solid line indicates time spent on the same ward. The timing of the ﬁrst positive sample for each case is indicated with
a cross. Case H subsequently developed a bloodstream infection.
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Rapid benchtop sequencing of Staphylococcus aureus and Clostridium difﬁcileﬁgure 2B. The extreme rarity of this spa-type in the UK
(no t5973 isolates held by the National Reference
Laboratory), and the fact they exhibited indistinguish-
able PFGE types, would normally be considered sufﬁ-
cient evidence for an outbreak. However, the isolates
showed methicillin heteroresistance (which impaired
initial detection of the outbreak) and differed in peni-
cillin and tetracycline sensitivity (table 1); no common
source was identiﬁed, casting doubt on the connection
between the ﬁrst seven cases and with the bloodstream
infection, which occurred after a further 8 weeks, but in
the absence of any contemporaneous patient MRSA
isolates.
No sequence differences were detected in the mapped
genomes between isolates from six of the carriage cases
(A, B, C, D, F and G); case E differed at a single site. The
two isolates (nasal swab and blood culture) from the
bloodstream infection case (H) were indistinguishable
and differed by three SNVs from the other cases. Given
previous estimated rates of short-term S aureus evolution
of 9.6 (95% CI 7.3 to 11.6)
4 and 7.9 (95% credibility
interval 4.8e12.8)
21 SNVs/genome/year, these data are
consistent with recent acquisition from a common
source. In contrast, the mean number of SNVs between
all pairs of S aureus isolates from the same unit from the
following month was 7541 (ﬁgure 2A). All the outbreak
cases (AeH) were mecA positive by PCR and sequencing;
however, two plasmids not present in MRSA252,
encoding the blaZ and tetK genes, were detected in seven
and ﬁve of the isolates, respectively. These genotypic
ﬁndings matched the phenotypic susceptibility results
(table 1).
As sequencing data provided support for an outbreak,
this directly led to implementation (and escalation with
subsequent cases) of intensive infection control super-
vision of the unit with visits up to four to ﬁve times per
day. Observations made resulted in retraining for
medical and nursing staff covering administration of
intravenous medication and taking blood cultures.
Additionally, isolation of all MRSA carriers was
implemented and reinforced.
NGS supports transmission of isolates during short periods
of shared ward exposure (MRSA cluster 2)
Six PantoneValentine leukocidin-positive MRSA isolates
were identiﬁed over 3 months (ﬁgure 2C,D). Five had
been inpatients on the same ward (Q, R, S, T and V)
(with overlapping stays of 1e2 days in four cases) and
one (U) was a relative of V. All were spa-type t657, which,
although relatively rare, has occurred sporadically in this
region. The isolates were also indistinguishable by PFGE.
Therefore, given the prolonged timescale, it was unclear
whether these cases reﬂected a genuine outbreak or
background circulation of related organisms. In fact,
only one SNV was detected among all six samples, indi-
cating a recent common source, whereas two isolates
originating from the same geographical area and with
the same spa and susceptibility proﬁles, but with slightly
different PFGE types and no known epidemiological
link, differed from the main cluster at 21 and 37 sites,
respectively. The sites were distributed throughout the
genome ruling out a single recombination event
accounting for all the differences (supplementary ﬁgure
1). Additionally, no variant sites were detected within the
mutS, mutS2 and mutL genes associated with hyper-
mutation.
22 The SNV differences are therefore consis-
tent with a shared ancestry 2e5 years earlier.
NGS refutes transmission between suspected linked cases
(C difﬁcile cluster 1)
The OUH infection control service identiﬁed three CDI
cases (B, C and D) occurring over 4 days among
Table 1 MRSA cluster 1, comparison of antibiotic susceptibility and associated genetic elements
Patient Sample date
Antibiotic susceptibility
Gene presence/
absence
Penicillin Tetracycline
blaZ tetK DD MIC DD MIC
A 25/7 R 2 S 0.094 + 
B 27/7 R 2 R 24 + +
C 27/7 R 4 S 0.094 + 
D (i) 5/8 R 3 R 24 + +
D (ii) 10/8 R 2 R 24 + +
E 8 / 8 R4 R3 2 + +
F 8/8 S 0.047 S 0.064 
G 8/8 R 3 S 0.094 + 
H (i) 28/9 R 4 R 24 + +
H (ii)* 29/9 R 2 R 24 + +
Screening swabs were obtained from patient D on two separate dates. All isolates were methicillin heteroresistant, appearing susceptible on
routine testing, despite detection of mecA by PCR and sequencing. This explains why isolate F appeared phenotypically penicillin susceptible
on DD and E testing. The mechanism of heteroresistance for these isolates has not yet been fully elucidated, although the penicillin-susceptible
methicillin-resistant phenotype has been described.
20
*The second isolate from patient H is from a positive blood culture.
DD, disc diffusion (R, resistant; S, susceptible); MIC, minimum inhibitory concentration (milligrams per litre).
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Rapid benchtop sequencing of Staphylococcus aureus and Clostridium difﬁcileinpatients on the same ward (ﬁgure 3A,B). While UK
Department of Health guidance
23 states that a cluster
should only be considered an ‘outbreak’ when the cases
share a strain type (eg, by MLST or PCR-ribotyping),
such information is slow to obtain. In practice, therefore,
such clusters are treated as presumptive outbreaks
requiring intensive management. Sequencing showed
that all three cases had different computationally
predicted sequence types (STs, ST2, ST10 and ST37) and
differed at >4000 sites distributed throughout the
genome (supplementary ﬁgure 2). With short-term C
difﬁcile evolution rates estimated from serial sampling of
91 patients with samples taken between 1 and 561 days
apart at 2.3 SNVs/genome/year (95% credibility interval
1.6e3.0). (Xavier Didelot, personal communication 20
January 2012, manuscript under review), recent trans-
mission between these cases can be excluded with
conﬁdence. However, a fourth case (A) that occurred
12 days previously, and was not initially included in the
infection control investigation, was indistinguishable
from case B; case A was found to have been in an adja-
cent side room to case B, strongly suggesting ward-based
transmission. Presentation of this sequencing data
backed transmission event to an outbreak review
meeting, resulted in a detailed infection control audit,
which in turn led to markedly improved cleaning of
equipment.
NGS demonstrates that isolates of the same strain type are
not necessarily linked by transmission (C difﬁcile cluster 2)
Three CDI cases (F, G and H) occurring over a 3-week
period in an elective surgical unit were suggestive of
transmission since the most recent previous CDI (E) had
occurred 6 months before (ﬁgure 3C,D). However,
isolates from the three cases were sufﬁciently genomi-
cally diverse to rule out transmission. Notably, two
isolates shared a sequence type (ST5) under the strain-
typing scheme used in OUH but differed at 144 sites
distributed throughout the genome (supplementary
ﬁgure 3), providing an example of the extra discrimi-
natory power of sequencing over existing typing schemes
in ruling out transmission.
NGS-based C difﬁcile surveillance, a reconstruction
All seven CDI cases occurring in one of the OUH
hospitals over 6 weeks were sequenced on the MiSeq
platform and compared with each other and with an
‘historical’ sequence database comprising 1185 isolates
from regional CDI cases occurring in the previous
3 years.
Four of the seven cases (ST3) formed a genetic cluster
containing variation at only two SNVs, indicating prob-
able transmission; these cases shared time and space on
the same ward around their CDI. The genetically most
similar historical CDI case differed from the four
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Figure 3 Clostridium difﬁcile cluster genetic and epidemiological relationships. (A and B) C difﬁcile cluster 1. (C and D) C difﬁcile
cluster 2. The left panels show the genetic relationships between cases as maximum likelihood trees, labelled with the number of
single nucleotide variants at which samples differ. Genetically indistinguishable cases are shown in the same circle. The right-hand
panels (B and D) show time spent on the same ward as a horizontal line for each case. The timing of the ﬁrst positive sample for
each case is indicated with a cross.
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Rapid benchtop sequencing of Staphylococcus aureus and Clostridium difﬁcilegenetically clustered cases at three SNVs (ﬁgure 4);
however, it occurred 3 years earlier and 30 miles way.
Therefore, no direct relationship could be discerned
between the historical cases and the current outbreak.
The three remaining cases in the group of seven
reconstruction cases (representing ST1, ST11 and ST13)
differed from the other four cases and from each other
at >3000 SNVs. The overall mean pairwise SNV differ-
ence between all reconstruction cases was 13012 SNVs.
One individual (ST1, ribotype-027), diagnosed on the
day of admission and last admitted 8 months previously,
yielded a C difﬁcile sequence indistinguishable from 11
previous CDI cases, including local strains from
6 months previously. Since this patient had not shared
inpatient time with any of the other cases and most of
the genetically related cases had occurred outside of
OUH hospitals, this may represent previously unsus-
pected community-based transmission, which could have
been investigated had sequence information been
available in 2010. No plausible hospital or community
patient source could be identiﬁed for the other two
cases; however, previous cases differing from them at
four to 10 SNVs were identiﬁed in the previous 6 months
to 3 years, consistent with a local strain origin.
DISCUSSION
This study provides strong evidence in two major
healthcare-associated pathogens, S aureus and C difﬁcile,
that benchtop sequencing can enhance hospital infec-
tion control through high precision support and rejec-
tion of transmission using genetic data. We also show this
technology offers turnaround times of under a week in
a format that, in contrast to molecular typing, is
organism independent.
The results obtained in this study were obtained
quickly enough to inﬂuence cluster investigations and in
the outbreaks described were used to inform the hospi-
tal’s response. Where suspected transmission events were
supported by sequencing data in two of the outbreaks
infection control supervision of measures to prevent
case-to-case spread was signiﬁcantly enhanced. In
contrast, increases in incidence without transmission
between infected patients still merit a response, for
example, clusters of genetically unrelated C difﬁcile cases
on wards have prompted a review in our hospitals of
antibiotic use and guidance. If such clusters were iden-
tiﬁed in patients with S aureus infection, this might
prompt, for example, review of line care or perioperative
care. Had the set of cases in the C difﬁcile surveillance
reconstruction been sequenced in real time, an outbreak
would have become apparent after the second case, and
it is possible that subsequent transmissions might have
been prevented, particularly as compliance with infec-
tion control measures was incomplete at the time of the
outbreak. Clearly formal evaluation of the use of the
technology in an appropriately controlled trial is needed
to determine the extent to which the control of these
outbreaks was, or would have been, enhanced by the
availability of sequence data.
Whole-genome sequencing provides the ultimate
resolution of genetic relationships. This offers two clear
beneﬁts for inference of transmission events. First,
putative transmission events between genetically very
distinct isolates can be refuted with conﬁdence. This is of
Figure 4 Potential for whole-
genome sequencing to enhance
Clostridium difﬁcile surveillance.
Genetic relationships between
cases are shown as a maximum
likelihood tree, labelled with the
number of single nucleotide
variants (SNVs) at which
samples differ. Genetically
indistinguishable cases are shown
in the same circle. Cases from an
existing database of sequenced
isolates are shown in grey circles
with the date of isolation. Four
cases arising during a 6-week
surveillance reconstruction are
shown in white circles. Three
additional cases sequenced as
part of the reconstruction differed
at >3000 SNVs from the cases
shown and are not shown in the
ﬁgure. The maximum likelihood
tree shown is consistent with data;
however, homoplasy was
observed at one of the variant
sites, 2464157, in the CD630
reference genome.
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Rapid benchtop sequencing of Staphylococcus aureus and Clostridium difﬁcileparticular value by comparison with widely used current
typing strategies that are unable to distinguish isolates
belonging to a prevalent strain type; for example, PCR-
ribotype-027 (NAP-1) accounts for w35% of C difﬁcile
strains in UK and North American hospitals.
24 25
Second, close genetic relationships combined with clin-
ical and epidemiological evidence can provide strong
evidence in favour of a putative transmission event,
justifying infection control intervention, as detailed
above. Notably, a genetic match in the absence of an
obvious epidemiological link may legitimately prompt
investigation of new routes of transmission, such as
the possible community transmission identiﬁed in our
C difﬁcile surveillance reconstruction. However, close
genetic links cannot be used in isolation to conﬁrm
transmission. For example, we identiﬁed genetically
similar cases separated by both time and space, empha-
sising the importance of analysing genetic data alongside
epidemiological information. The main limitation of this
study is it is not large enough to provide a formal
comparison with existing technology including a health
economic evaluation. Additionally, although we used
the Illumina MiSeq platform, other similar benchtop
technology exists, for example, Ion Torrent (Life Tech-
nologies, Guildford, Connecticut, USA), or is under
development, for example, Oxford Nanopore (Oxford
Nanopore Technologies, Oxford, UK).
NGS technology is widely generalisable to human
bacterial pathogens
26 and has been used previously to
investigate transmission of infectious disease.
2e5
Although the beneﬁts of rapid sequencers have been
shown in high-proﬁle national outbreaks,
6e8 we provide
the ﬁrst demonstration of rapid sequencing in
a benchtop format applied to routine patient care and
healthcare-associated pathogens. Existing typing
schemes, such as spa, PFGE, PCR-ribotyping and MLST,
have established a framework in the application of
genetic data in outbreak investigation. However, the
organism-speciﬁc application of these strain-typing
methods, often requiring isolates to be sent to a speciﬁc
reference laboratory, in practice means that many
infection clusters remain untyped. Benchtop sequencing
builds upon existing typing expertise, offering rapidly
available and increased resolution data from an
organism-independent platform. This means that
a single technology will provide the capacity for indi-
vidual hospital laboratories to support outbreak investi-
gation for a range of pathogens and allow infection
control personnel to efﬁciently target resources to
genuine outbreaks. Sequencing costs are falling
rapidly,
27 28 with the prospect within 12 months of being
able to obtain complete accurate pathogen sequences in
hours, and for as little as US$10 per sequence.
29 It is
therefore likely that benchtop sequencing will soon be
comparable in price to existing molecular typing while
offering consider additional beneﬁts. As well as identi-
fying transmissions, the reproducible and digital nature
of locally generated sequence data make these ideal for
sharing in national and potentially international
surveillance, for sequence-based resistance prediction
and for precise generic species identiﬁcation.
26
The case studies in this pilot study provide a clear
rationale for future work undertaking formal compari-
sons of benchtop NGS with existing local and national
typing schemes. Such comparisons will need to include
formal health economic assessments that account for the
capital expense of establishing benchtop NGS equip-
ment and expertise in a laboratory, as well as the
potential cost-savings associated with more focused
cluster investigation, and infection control interven-
tions. The improved accuracy in identifying within-
hospital transmission should also lead to better metrics
of hospital infection control performance and provide
an opportunity for further reductions in the incidence
of healthcare-associated infections and hence improve-
ments in patient outcomes.
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